18 November 2022 - - Switzerland-based oncology company Novocure (NASDAQ: NVCR) has opened a new office in Montreal to expand and support its growing business in Canada, the company said.

Novocure is working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields).

TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.

Novocure said I tchose Montreal because of its innovative culture, world-class universities and hospitals, access to top talent and quality of life, including investments the city is making in its public transportation system.

Novocure inaugurated its Montreal office on Nov. 2, welcoming Novocure leadership and colleagues; Dr. David Roberge, Professor of Radiology, Radiation Oncology and Nuclear at the CHUM Research Centre and Future president of the Canadian Association of Radiation Oncology; Shannon LaHay, chief executive officer, Brain Tumour Foundation of Canada; and Romina Ferro, Marketing and Communications Manager Brain Tumour Foundation of Canada, among other guests to celebrate this milestone for the company.

While Novocure's physical office presence in Canada is new, Novocure's footprint in Canada began in 2013, when Canadian institutions began participating in Novocure's clinical trials evaluating TTFields.

To date, 14 Canadian institutions four of which are in Quebec have participated in six clinical trials involving TTFields.